Arhive aprilie 2021

Mieloame

Nr.Numele studiuluiStatusLocatia/Locatiile studiului
1A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)In curs de recrutateResearch Site, Bucharest, Romania, 022328Research Site, Bucharest, Romania, 030171Research Site, Bucharest, Romania, 050098Research Site, Bucuresti, Romania, 020125Research Site, Cluj-Napoca, Romania, 400124Research Site, Iasi, Romania, 700483Research Site, Oradea, Romania, 410469Research Site, Sibiu, Romania, 550245Research Site, Timisoara, Romania, 300079
2Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)Activ, inca nu se recruteazaResearch Site, Brasov, Romania, 500152Research Site, Bucharest, Romania, 030171Research Site, Bucharest, Romania, 050098Research Site, Bucuresti, Romania, 020125Research Site, Bucuresti, Romania, 022328Research Site, Cluj-Napoca, Romania, 400124Research Site, Craiova, Romania, 200143
3Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1)Activ, inca nu se recruteazaLocal Institution, Brasov, Romania, 500152Local Institution, Bucuresti, Romania, 030171Local Institution, Bucuresti, Romania, 020125Local Institution, Bucuresti, Romania, 050098Local Institution, Bucuresti, Romania, 22328Local Institution, Iasi, Romania, 700483
4Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)Activ, inca nu se recruteazaHyperclnical MedLife PDR Vulturului Brasov, Hematology Department, Braşov, Romania, 500366Colentina Clinical Hospital, Department of Hematology, Bucharest, Romania, 020125Bucharest University Emergency Hospital, Department of Hematology, Bucharest, Romania, 050098
5A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple MyelomaActiv, inca nu se recruteazaBrasov, RomaniaBucharest, RomaniaIasi, Romania
6A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)Activ, inca nu recruteazaRO-02, Braşov, RomaniaRO-01, Bucharest, Romania

Mezotelioame

Nr.Numele studiuluiStatusLocatia/Locatiile studiului
1Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)Activ, inca nu se recruteazaResearch Site, Craiova, Romania, 200385
2Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)Activ, inca nu se recruteazaLocal Institution, Bucharest, Romania, 020122Local Institution, Bucuresti, Romania, 021389Local Institution, Craiova, Romania, 200347Local Institution, Romania, Romania, 400015

Limfoame

Nr.NumelestudiuluiStatusLocatia/Locatiilestudiului
1Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-4)                                            Activ, nu se recruteazaSp. Judetean de Urgenta Dr. Constantin Opris Baia Mare, Baia Mare, Romania, 430031S.C. Policlinica de Diagnostic Rapid S.A., Brasov, Romania, 500152Fundeni Clinical Institute, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucharest, Romania, 030171Sp. Univ. de Urgenta Militar Central Dr. Carol Davila, Bucuresti, Romania, 010825Spitalul Clinic Colentina, Bucuresti, Romania, 020125Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania, 200143Institutul Regional de Oncologie Iasi, Iasi, Romania, 700111Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Spitalul Clinic Judetean de Urgenta Targu-Mures, Targu-Mures, Romania, 540136
2Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-3)Activ, inca nu se recruteazaBrasov, Romania, 500152Bucharest, Romania, 030171Bucuresti, Romania, 010825Bucuresti, Romania, 020125Bucuresti, Romania, 022328Cluj-Napoca, Romania, 400015Craiova, Romania, 200143Targu-Mures, Romania, 540136
3A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma  Activ, inca nu se recruteazaInstitut Clinic Fundeni, Bucuresti, Romania, 22328Spitalul Clinic de Urgenta pentru Copii M.S. Curie, Bucuresti, Romania, 41451Institutul Oncologic ‘Prof Dr. Ion Chiricuta’ Cluj-Napoca , Cluj-Napoca, Romania, 400015Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea, Oradea, RomaniaSpitalul Clinic de Urgenta pentru Copii ‘Louis Turcanu’, Timisoara, Romania, 300011
4Dose Optimization Study of Idelalisib in Follicular LymphomaIn curs de recrutareSpitalul Judetean de Urgenta Dr.Constantin Opris Baia Mare, Baia Mare, RomaniaSpitalul Clinic Coltea, Bucuresti, RomaniaInstitutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca, RomaniaInstitutul Regional De Oncologie IASI, Iasi, Romania
5ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (ECHELON-2)Activ, inca nu se recruteazaInstitutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucuresti, Romania, 030171Institutul Oncologic „Prof. Dr. I. Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania, 400015Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular, Targu Mures, Romania, 540136
6Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaActiv, inca nu se recruteazaPoliclinica de Diagnostic Rapid SA, Brasov, Romania, 500152Spitalul Clinic Colentina, Bucuresti, Romania, 020125Spitalul Clinic Coltea, Bucuresti, Romania, 030171Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, Romania, 540042
7A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)In curs de recrutareMorphoSys Research Site, Bucharest, Romania, 022328MorphoSys Research Site, Bucharest, Romania, 30171MorphoSys Research Site, Iaşi, Romania, 700483
8Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.In curs de recrutareCluj NapocaIon Chiricuta Oncology Institute, Cluj Napoca, Romania, 400015 Contact: Ciprian Tomuleasa, MD    0040741337480    ciprian.tomuleasa@umfcluj.ro   Contact: Catalin Vlad, MD    0040264598362    catalinvlad@yahoo.it  

Leucemii

Nr.Numele studiuluiStatusLocatia/Locatiile studiului
1Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)Activ, inca nu se recruteazaInstitutul Regional de Oncologie Iași, Iași, Romania, 20125Spitalul Clinic Colentina, Bucuresti, Romania, 20125Spitalul Clinic Coltea, Bucuresti, Romania, 20125Spitalul Universitar de Urgenta Bucuresti, Bucuresti, Romania, 20125Institutul Clinic Fundeni, Bucuresti, Romania, 22328Institutul Oncologic „Prof. Dr. Ion Chiricuţă” Cluj Napoca, Cluj-Napoca, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania, 200143Spitalul Clinic Judetean de Urgenta Târgu-Mureş (4005), Târgu-Mureş, Romania, 540042Spitalul Clinic Judetean de Urgenta Târgu-Mureş (4008), Târgu-Mureş, Romania, 540136
2A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019)Activ, inca nu se recruteazaInstitutul Oncologic ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Cluj, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Sectia Clinica Hematologie, Craiova, Dolj, Romania, 200136Spitalul Universitar de Urgenta Militar Central „Dr. Carol Davila” Bucuresti, Bucuresti, Romania, 010825Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania, 030171
3Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia.Acitv, inca nu se recruteazaNovartis Investigative Site, Bucharest, District 2, Romania, 022328Novartis Investigative Site, Tg Mures, Mures, Romania, 540136Novartis Investigative Site, Craiova, Romania, 200136Novartis Investigative Site, Iasi, Romania, 700483
4A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete RemissionActiv, inca nu se recruteazaSite RO40005, București, Romania
5Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsActiv, inca nu se recruteazaNovartis Investigative Site, Bucharest, District 2, Romania, 022328Novartis Investigative Site, Bucharest, Romania, 030171Novartis Investigative Site, Cluj-Napoca, Romania, 400124Novartis Investigative Site, Craiova, Romania, 200136Novartis Investigative Site, Timisoara, Romania, 300079
6Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALLActiv, inca nu se recruteazaResearch Site, Bucharest, Romania, 022328Research Site, Cluj-Napoca, Romania, 400177
7Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaIn curs de recrutareInsitutul Clinic Fundeni, Sectia de Transplant Medular, Bucharest, Romania, Contact: Anca Colita, MD PhD, ancacolita@yahoo.com Principal Investigator: Anca Colita, MD PhD         University of Medicine and Pharmacy V. BABES, Emergency Children’s Hospital LOUIS TURCANU, III. Clinic of Pediatrics , Department of Onco-hematology and Bone Marrow Transplantation, Timişoara, Romania, Contact: Cristian Jinca, MD PhD, cristian_jinca@yahoo.com   Principal Investigator: Cristian Jinca, MD PhD  
8A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line TherapyActiv, inca nu se recruteazaInstitutul Clinic Fundeni, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucharest, Romania, 030171Spitalul Clinic Judetean de Urgenta Sf Spiridon Iasi   , Iasi, Romania, 700111Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Spitalul Clinic Municipal de Urgenta Timisoara, Timisoara, Romania, 300079
9A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic LeukemiaActiv, inca nu se recruteazaFundeni Clinical Inst. ; Hematology Dept., Bucharest, Romania, 022328Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, Romania, 700483Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania, 540136
10A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to ImatinibActiv, inca nu se recruteazaLocal Institution, Bucharest, Romania, 022322
11Safety, Tolerability, Pharmacokinetics and Activity of K0706In curs de recrutareSpitalul Clinic Colentina Recruiting Bucuresti, Romania, 020125 Spitalul Clinic Coltea Recruiting Bucuresti, Romania, 030171 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca Recruiting Cluj-Napoca, Romania, 400124 Spitalul Clinic Municipal Filantropia Craiova Recruiting Craiova, Romania, 200143 Spitalul Clinic Judetean de Urgenta Targu Mures Recruiting Târgu Mureș, Romania, 540136
12An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALLIn curs de recrutareSpitalul Clinic Municipal de Urgenta Timisoara Recruiting Timisoara, Timis, Romania, 300021 Spitalul Clinic Colentina Recruiting Bucuresti, Romania, 020125 Spitalul Universitar de Urgenta Bucuresti Recruiting Bucuresti, Romania, 50098 Institutul Regional de Oncologie Iasi Recruiting Iasi, Romania, 700483

Hepatocarcinoame

Nr.Numele studiuluiStatusLocatia/Locatiile studiului
1A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)In curs de recrutareLocal Institution, Brasov, Romania, 500091, Contact: Site 0060         Local Institution, Bucharest, Romania, 022328, Contact: Site 0078         Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0232         Local Institution, Constanta, Romania, 900591, Contact: Site 0242         Local Institution, Craiova, Romania, 200347, Contact: Site 0074         S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Romania, 300166, Contact: Roxana-Ioana Scheusan, Site 0070    +40745146020 
2Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)Activ, inca nu se recruteazaCluj-Napoca, Cluj, Romania, 400015Brasov, Romania, 500019
3A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)In curs de recrutareLocal Institution, Craiova, Dolj, Romania, 200347, Contact: Site 0103         Local Institution, Bucharest, Romania, 22328, Contact: Site 0164         Local Institution, Cluj Napoca, Romania, 400015, Contact: Site 0165         Local Institution, Craiova, Romania, 200385, Contact: Site 0208         Local Institution, Timisoara, Romania, 300166, Contact: Site 0163   
4Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)Activ, inca nu se recruteazaSpitalul Pelican Impex SRL- Sectia Oncologie Medicala, Bihor, RomaniaInstitutul Clinic Fundeni – Sectia Oncologie Medicala, Bucuresti, RomaniaClinica Bendis – Oncologie Medicala, Cluj, RomaniaCentrul de Oncologie ONCOLAB, Dolj, RomaniaInstitutul Regional de Oncologie Iasi – Sectia Oncologie Medicala, Iaşi, RomaniaSC DACMED SRL – Oncologie, Prahova, RomaniaSpitalului Clinic Judetean de Urgenta – Sectia Oncologie Medicala, Sibiu, RomaniaSpitalul Judetean de Urgenta „Sf. Ioan Cel Nou” – sectia Oncologie Medicala, Suceava, Romania
5Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)In curs de recrutareExelixis Clinical Site #204 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400015 Exelixis Clinical Site #211 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400015 Exelixis Clinical Site #202 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400641 Exelixis Clinical Site #206 Active, not recruiting Bucuresti, Romania, 022328 Exelixis Clinical Site #209 Active, not recruiting Iaşi, Romania, 700483
6Contrast Enhanced Ultrasound Guidance Biopsy for the Diagnosis of Liver Tumors (ConCLUDe)In curs de recrutareRegional Institute of Gastroenterology and Hepatology „Octavian Fodor” Recruiting Cluj-Napoca, Please Enter The State Or Province, Romania, 400126 Contact: Tudor Mocan    +40 799 861946    Mocan.Tudor@umfcluj.ro    Contact: Ioana Rusu       ioana.russu@yahoo.com      

Diverse

Nr.NumelestudiuluiStatusLocatia/Locatiilestudiului
1Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.Activ, inca nu recruteazaSC Oncolab SRL, Craiova, Dolj, Romania, 200385S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Timis, Romania, 300166SC ONCOCENTER Oncologie Clinica SRL, Timisoara, Timis, Romania, 300210Spitalul Clinic C.F. 2 Bucuresti. Departament Oncologie, Sectia Medicala 2, Bucuresti, Romania, 011464             
2Pan Tumor Nivolumab Rollover StudyIn curs de recrutareLocal Institution, Bucharest, Romania, 022328, Contact: Site 0129         Local Institution, Cluj Napoca, Romania, 400015, Contact: Site 0135         Local Institution, Cluj Napoca, Romania, 400641, Contact: Site 0127         Local Institution, Oradea, Romania, 440445, Contact: Site 0133   
3A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)In curs de recrutareLocal Institution, Bucuresti, Romania, 022328Local Institution, Cluj-Napoca, Romania, 400015Local Institution, Craiova, Romania, 200347Local Institution, Floresti, Romania, 407280Local Institution, Timisoara, Timis, Romania, 300239
4Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)Activ, inca nu recruteazaS.C Delta Health Care S.R.L, Bucuresti, Romania, 014142S.C Medisprof S.R.L., Cluj-Napoca, Romania, 400641S.C Centrul de Oncologie Sf. Nectarie S.R.L., Craiova, Romania, 200347S.C Oncocenter Oncologie Clinica S.R.L., Timişoara, Romania, 300166
5Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)In curs de recrutareS.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102), Oradea, Bihor, Romania, 410469, Contact: Study Coordinator    +40746103306      SC Radiotherapy Center Cluj SRL ( Site 1105), Comuna Floresti, Cluj, Romania, 407280, Contact: Study Coordinator    +40742206212      S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103), Craiova, Dolj, Romania, 200347, Contact: Study Coordinator    +40727774974      Spitalul PDR Medlife ( Site 1106), Brasov, Romania, 500152, Contact: Study Coordinator    +40722559551      S.C.Focus Lab Plus S.R.L ( Site 1101), Bucuresti, Romania, 021389, Contact: Study Coordinator    +40721298677      S.C.Gral Medical S.R.L ( Site 1104), Bucuresti, Romania, 031422, Contact: Study Coordinator    +40723954705      Medisprof ( Site 1107), Cluj Napoca, Romania, 400641, Contact: Study Coordinator    +40751274636    
6Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal CancerIn curs de recrutareResearch Site, Bucharest, Romania, 022328Research Site, Cluj-Napoca, Romania, 400015Research Site, Cluj-Napoca, Romania, 400124Research Site, Timisoara, Romania, 300239
7An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have SpreadIn curs de recrutareLocal Institution, Bucharest, Romania, 022328, Contact: Site 0045         Local Institution, Craiova, Romania, 200347, Contact: Site 0041  
8A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)In curs de recrutareProf. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania, 400015Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-napoca, Romania, 400015ONCOMED – Medical Centre, Timisoara, Romania, 300239
9Durvalumab Long-Term Safety and Efficacy Study (WAVE)In curs de recrutareResearch Site, Craiova, Romania, 200347Research Site, Suceava, Romania, 720237
10A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)In curs de recrutareCentrul de Oncologie Sfantul Nectarie, Craiova, Romania, 200347
11Avelumab Program Rollover StudyIn curs de recrutareSpitalul Clinic Municipal „Dr. Gavril Curteanu” Oradea – Centrul Oncologie Medicala, Oradea, Romania, 410469, Contact: simonamihutiu@yahoo.com,   Principal Investigator: Simona Mihutiu  
12Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesActiv, inca nu recruteazaNovartis Investigative, Bucuresti, Romania, 011863
13AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)Activ, inca nu se recruteazaEmergency Clinical County Hospital Brasov, Brasov, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaColtea Clinical Hospital, Bucharest, Romania
14A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (EUMDS)In curs de recrutareFundeni CLinical Institute, Clinic of Hematology, Bucharest, Romania
15NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk WallActiv, inca nu se recruteazaInstitutul Oncologic Bucuresti Bucharest, Romania Spitalului Universitar de Urgenta Militar Central Bucharest, Romania Amethyst-Cluj Floresti, Romania County Hospital ‘Dr Gavril Curteanu’ Oradea, Romania County Hospital, Targu Mures Targu Mures, Romania Municipal Emergency Hospital Timisoara, Romania

Cancerele urinare

Nr.NumelestudiuluiStatusLocatia/Locatiilestudiului
1Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell CancerActiv, inca nu se recruteazaOncomed SRL, Timisoara, JUD. Timis, Romania, 300239Institutul Oncologic „Prof.Dr.I.Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania, 400015
2An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerIn curs de recrutareBucharest, RomaniaCluj-Napoca, RomaniaCraiova, RomaniaIasi, Romania
3A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)Activ, inca nu se recruteaza„Prof. Dr. Ion Chiricuta” Oncology Institute, Cluj-Napoca, Romania, 400015S.C. Medisprof S.R.L., Cluj-Napoca, Romania, 400641″Sfantul Nectarie” Oncology Center, Craiova, Romania, 200347Oncomed SRL, Timisoara, Romania, 300239
4Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901)In curs de recrutareLocal Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0191         Local Institution, Craiova, Romania, 200347, Contact: Site 0187     
5A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary TractActiv, inca nu se recruteazaOncopremium Team Srl, Baia Mare, Romania, 430291Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Spital de zi-Parter, Cluj-Napoca, Romania, 400015Centrul de Oncologie Sfantul Nectarie, Craiova, Romania, 200347Centrul de Radioterapie AMETHYST, Floresti, Romania, 407280Oncomed SRL; Oncologie, Timisoara, Romania, 300239
6An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)Activ, inca nu se recruteazaLocal Institution, Bucuresti, Romania, 021389Local Institution, Craiova, Romania, 200347Local Institution, Floresti, Romania, 407280Local Institution, Timisoara, Timis, Romania, 300239
7A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBCIn curs de recrutareInstitute Of Oncology „Prof.Dr.Alexandru Trestioreanu” Bucharest, Bucharest, Romania, 020122, Contact: Aurelia Alexandru, Site 0058         Local Institution, Craiova, Romania, 200347, Contact: Site 0076
8A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal)In curs de recrutareCounty Hospital Alba; Oncology, Alba Iulia, Romania, 510073Centrul Medical Focus; Oncologie medicala, Bucharest, Romania, 021389University Clinical Emergency Hospital Bucharest, Bucharest, RomaniaInstitutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania, 022328Sanador Medical Center; Medical Oncology, Bucuresti, RomaniaSpitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta, Constanta, Romania, 900591Institutul Regional de Oncologie Iasi, Iasi, Romania, 700483Spitalul Municipal Ploiesti, Ploiesti, Romania, 100337Oncomed SRL; Oncologie, Timisoara, Romania, 300239Oncocenter Timisoara , Timişoara, Romania, 300166
9A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)Activ, inca nu se recruteazaFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician.      Baia Mare, Romania, 430110Cluj-Napoca, Romania, 400058Craiova, Romania, 200347
10A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)In curs de recrutareLocal Institution, Bucharest, Romania, 50659, Contact: Site 0201         Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0200         Local Institution, Craiova, Romania, 200347, Contact: Site 0199         Local Institution, Lasi, Romania, 700483, Contact: Site 0202     
11An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActiv, inca nu se recruteazaLocal Institution, Bucharest, Romania, 014142, Contact: Site 0076         Local Institution, Bucharest, Romania, 020122, Contact: Site 0061         Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0056         Local Institution, Constanta, Romania, 900591, Contact: Site 0059         Local Institution, Craiova, Romania, 200347, Contact: Site 0065 
12Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)Activ, inca nu se recruteazaSpitalul Judetean de Urgenta Dr Constantin Opris, Baia Mare, Romania, 430031Institute Of Oncology Bucharest; Medical Oncology, Bucharest, Romania, 022338Oncology Center Sf. Nectarie, Craiova, Romania, 200347
13Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell CarcinomaActiv, inca nu se recruteazaMedisprof SRL, Cluj-Napoca, RomaniaProf Dr I Chiricuta Institute of Oncology, Cluj-Napoca, RomaniaOncology Center Sfantul Nectarie, Craiova, RomaniaOncocenter Clinical Oncology, Timisoara, Romania
14A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)Activ, inca nu se recruteazaInstit. Prof.Dr.Ion Chiricuta, Cluj-Napoca, Romania, 400015Sf. Nectarie Oncology Center, Craiova, Romania, 200347
15A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)In curs de recrutareCentrul de Oncologie Sfantul Nectarie, Craiova, Dolj, Romania, 200347Oncolab SRL, Craiova, Dolj, Romania, 200385Medisprof SRL , Cluj-Napoca, Romania, 400461Clinical Emergency Hospital of Constanta, Constanta, Romania, 900591Center of Oncology Euroclinic, Iasi, Romania, 700106Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Oncocenter – Oncologie Clinica SRL, Timisoara, Romania, 300166
16Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)In curs de recrutareSpitalul Clinic Judetean de Urgenta ‘Sf Apostol Andrei’ Constanta Not yet recruiting Constanta, Romania, 900591
17A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActiv, nu se recruteazaLocal Institution Bucharest, Romania, 020122 Local Institution Cluj-Napoca, Romania, 400015 Local Institution Constanta, Romania, 900591 Local Institution Craiova, Romania, 200347
18Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)Activ, nu se recruteazaLocal Institution Bucharest, Romania, 022328 Local Institution Craiova, Romania, 200385 Local Institution Iasi, Romania, 700106 Local Institution Timisoara, Romania, 300167
19A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)In curs de recrutareLocal Institution Not yet recruiting Bucharest, Romania, 022328 Contact: Site 0039          Local Institution Not yet recruiting Cluj-Napoca, Romania, 400015 Contact: Site 0014          Local Institution Not yet recruiting Craiova, Romania, 200347 Contact: Site 0013         
20Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)In curs de recrutareS.C. Radiotherapy Center Cluj S.R.L ( Site 0252) Recruiting Cluj-Napoca, Cluj, Romania, 407280 Contact: Study Coordinator    +40742206212       S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248) Recruiting Craiova, Dolj, Romania, 200347 Contact: Study Coordinator    +40722161545      

Cancerele pielii

Nr.NumelestudiuluiStatusLocatia/Locatiilestudiului
1A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaIn curs de recrutareLocal Institution, Bucharest, Romania, 022328, Contact: Site 0066         Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0070         Local Institution, Craiova, Romania, 200347, Contact: Site 0067         Local Institution, Lasi, Romania, 700483, Contact: Site 0069
2A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaIn curs de recrutareLocal Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0070         Local Institution, Craiova, Romania, 200347, Contact: Site 0071         Local Institution, Floresti, Romania, 407280, Contact: Site 0120         Local Institution, Oradea, Romania, 410469, Contact: Site 0073
3Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)In curs de recrutareLocal Institution, Bucharest, Romania, 020122, Contact: Site 0021         Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0047         Local Institution, Craiova, Romania, 200347, Contact: Site 0020    
4An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)Activ, inca nu se recruteazaInstitute Of Oncology „Prof.Dr.Alexandru Trestioreanu” Bucharest, Bucharest, Romania, 022328Sf. Nectarie Oncology Center, Craiova, Romania, 200347
5Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)Activ, inca nu se recruteazaLocal Institution, Craiova, Romania, 200347Local Institution, Romania, Romania, 400015
6A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionIn curs de recrutareNova Clin Medical Research Center, Timisoara, Romania, 300696, Contact: Alexandru Bolocan, Site 0030   
7Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)In curs de recrutareSpitalul Universitar CF Cluj-Napoca ( Site 1103)        RecruitingCluj-Napoca, Cluj, Romania, 400015, Contact: Study Coordinator    +40724283983      S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1101), Craiova, Dolj, Romania, 200347, Contact: Study Coordinator    +40727774974      S C Oncocenter Oncologie Medicala S R L (Site 1106), Timisoara, Timis, Romania, 300166, Contact: Study Coordinator    +40745146020      Hifu Terramed Conformal SRL ( Site 1111), Bucharest, Romania, 031864, Contact: Study Coordinator    +40723599588      S.C.Focus Lab Plus S.R.L ( Site 1107), Bucuresti, Romania, 021389, Contact: Study Coordinator    +40721298677      Cardiomed SRL Cluj-Napoca ( Site 1104), Cluj-Napoca, Romania, 400015, Contact: Study Coordinator    +40724543672      S C Pelican Impex SRL ( Site 1108), Oradea, Romania, 410450, Contact: Study Coordinator    +40746103306      Policlinica Oncomed SRL ( Site 1105), Timisoara, Romania, 300239, Contact: Study Coordinator    +40744571617     
8A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)Activ, inca nu se recruteazaCentrul de Oncologie Sfantul Nectarie, Craiova, Dolj, Romania, 200347Oncolab SRL, Craiova, Dolj, Romania, 200385Medisprof SRL , Cluj-Napoca, Romania, 400461Clinical Emergency Hospital of Constanta, Constanta, Romania, 900591Center of Oncology Euroclinic, Iasi, Romania, 700106Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Oncocenter – Oncologie Clinica SRL, Timisoara, Romania, 300166

Cancere tiroidiene

Nr.Numele studiuluiStatusLocatia/Locatiile studiului
1A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)In curs de recrutareBucharest, Romania, 10825, Contact: Contact    1-888-EXELIXIS (888-393-5494)      Bucharest, Romania, 11863, Contact: Contact    1-888-EXELIXIS (888-393-5494)      Cluj-Napoca, Romania, 400058, Contact: Contact    1-888-EXELIXIS (888-393-5494)      Cluj-Napoca, RomaniaTimisoara, Romania, 300723
2A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted TherapyIn curs de recrutareExelixis Clinical Site #149, Cluj-Napoca, Cluj, Romania, 400015Exelixis Clinical Site #150, Craiova, Dolj, Romania, 200385Exelixis Clinical Site #142, Timişoara, Timis, Romania, 300166Exelixis Clinical Site #146, Bucuresti, Romania, 011863
3A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileActiv, inca nu se recruteazaFacility #1, Cluj-Napoca, Cluj, Romania, 400058Facility #1, Bucharest, Romania, 11863
4An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerActiv, inca nu se recruteazaInvestigational Site Number 1801, Bucharest, Romania